Cargando…
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells()
Malignant pleural mesothelioma (MPM) is a progressive malignancy associated to the exposure of asbestos fibers. The most frequently inactivated tumor suppressor gene in MPM is CDKN2A/ARF, encoding for the cell cycle inhibitors p16(INK4a) and p14(ARF), deleted in about 70% of MPM cases. Considering t...
Autores principales: | Bonelli, Mara A., Digiacomo, Graziana, Fumarola, Claudia, Alfieri, Roberta, Quaini, Federico, Falco, Angela, Madeddu, Denise, La Monica, Silvia, Cretella, Daniele, Ravelli, Andrea, Ulivi, Paola, Tebaldi, Michela, Calistri, Daniele, Delmonte, Angelo, Ampollini, Luca, Carbognani, Paolo, Tiseo, Marcello, Cavazzoni, Andrea, Petronini, Pier Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508477/ https://www.ncbi.nlm.nih.gov/pubmed/28704762 http://dx.doi.org/10.1016/j.neo.2017.05.003 |
Ejemplares similares
-
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2018) -
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019) -
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
por: La Monica, Silvia, et al.
Publicado: (2020) -
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
por: Terenziani, Rita, et al.
Publicado: (2022) -
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
por: Bonelli, Mara, et al.
Publicado: (2020)